-
1001
-
1002
The age-adjusted international prognostic index 2 (A-FLIPI2) for elderly patients with follicular lymphoma
Published 2025-02-01Get full text
Article -
1003
-
1004
-
1005
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Published 2025-02-01Get full text
Article -
1006
-
1007
-
1008
-
1009
-
1010
-
1011
Lipid disorders in patients of 15 to 64 years old in a policlinic of Rodas municipality.
Published 2006-04-01“…<strong>Background:</strong> Since long time ago clinic medicine established the inexorable progress or development of the human arteriosclerosis, a disease expressed through complications as coronary and cerebrovascular ischemia and obliterant arteriosclerosis of inferior limbs, among others. …”
Get full text
Article -
1012
Synergistic potential of α-Phellandrene combined with conventional antifungal agents and its mechanism against antibiotic resistant Candida albicans
Published 2024-02-01“…Further, the synergistic potential was evaluated by employing a time kill assay and a checkerboard technique, respectively, which revealed after 16 h, the colony count of C. albicans cells ATCC90028 (2.56 ± 0.33) and MTCC277 (2.53 ± 0.33) dropped by a log10 when treated with a combination of α-Phellandrene and Fluconazole and α-Phellandrene and amphotericin B exhibited synergy against both C. albicans strains ATCC90028 and MTCC277 (2.42 ± 0.28 and 2.00 ± 0.21) log10 reduction in colony count, respectively, Additionally, 16–624-fold increase in the antifungal efficacy of clinical medicines, with total cell death occurring after 16 h. α-Phellandrene and antifungal drugs were tested in combination with the osmoprotectant test, ergosterol test and FESEM observations to determine their modes of action. …”
Get full text
Article